Phase 3 Recruiting Academic/Other
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radi…
Sponsor: NRG Oncology
NCT ID: NCT04852887
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- University of South Alabama Mitchell Cancer Institute — Mobile, Alabama
- Kingman Regional Medical Center — Kingman, Arizona
+ 809 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares 6 months of human epidermal growth factor receptor 2 (HER2)-targeted therapy to 12 months of HER2-targeted therapy for the treatment of HER2-positive (+) breast cancer in patients that had a pathologic complet…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06876714
Locations: - Cancer Center at Saint Joseph's — Phoenix, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
+ 677 more sites in the U.S.
Phase 3 Recruiting NIH
This phase III trial compares the addition of an immunotherapy drug (durvalumab) to usual chemotherapy versus usual chemotherapy alone in treating patients with MammaPrint High 2 Risk (MP2) stage II-III hormone receptor positive, HER2 nega…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06058377
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Katmai Oncology Group — Anchorage, Alaska
- University of Arizona Cancer Center-Orange Grove Campus — Tucson, Arizona
+ 539 more sites in the U.S.
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Mercy Hospital Fort Smith — Fort Smith, Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
+ 378 more sites in the U.S.
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Locations: - Research Site — Dothan, Alabama
- Research Site — Phoenix, Arizona
- Research Site — Tucson, Arizona
+ 145 more sites in the U.S.
Phase 3 Recruiting Industry
This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06393374
Locations: - Infirmary Cancer Care ( Site 0001) — Mobile, Alabama
- Ironwood Cancer & Research Centers-Research ( Site 0054) — Chandler, Arizona
- MemorialCare Orange Coast Medical Center ( Site 9501) — Fountain Valley, California
+ 87 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This phase III trial compares proton craniospinal irradiation (pCSI) to involved-field radiation therapy (IFRT) for the treatment of breast or non-small cell lung cancer that has spread from where it first started to the cerebrospinal flui…
Sponsor: NRG Oncology
NCT ID: NCT06500481
Locations: - Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- University of Arkansas for Medical Sciences — Little Rock, Arkansas
- UC San Diego Health System - Encinitas — Encinitas, California
+ 55 more sites in the U.S.
Phase 3 Recruiting Industry
This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine…
Sponsor: Olema Pharmaceuticals, Inc.
NCT ID: NCT06016738
Locations: - Clinical Trial Site — Tucson, Arizona
- Clinical Trial Site — Fountain Valley, California
- Clinical Trial Site — Glendale, California
+ 44 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth fa…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06312176
Locations: - Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
- Banner MD Anderson Cancer Center-Oncology ( Site 0004) — Gilbert, Arizona
- Providence Medical Foundation-Oncology ( Site 0020) — Fullerton, California
+ 43 more sites in the U.S.
Phase 3 Recruiting Industry
Researchers are looking for other ways to treat breast cancer (BC) that is hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) and either unresectable locally advanced or metastatic. * HR positive (H…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT07060807
Locations: - Southern Cancer Center (SCC) ( Site 8000) — Daphne, Alabama
- The University of Arizona Cancer Center - North Campus ( Site 0055) — Tucson, Arizona
- Los Angeles Hematology Oncology Medical Group ( Site 0026) — Los Angeles, California
+ 31 more sites in the U.S.
Phase 3 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of BGB-43395 in combination with letrozole compared with investigator's choice of cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) in combination with letrozole in patients…
Sponsor: BeOne Medicines
NCT ID: NCT07492641
Locations: - Alabama Oncology Princeton — Birmingham, Alabama
- Alaska Oncology and Hematology, Llc — Anchorage, Alaska
- Ironwood Cancer and Research Centers Chandler Ii — Chandler, Arizona
+ 30 more sites in the U.S.
Phase 3 Recruiting Industry
This study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after…
Sponsor: Hoffmann-La Roche
NCT ID: NCT05894239
Locations: - Banner Health MD Anderson AZ — Gilbert, Arizona
- Disney Family Cancer Center — Burbank, California
- City of Hope — Corona, California
+ 17 more sites in the U.S.